CSA Medical
CSA Medical develops spray cryotherapy devices, specifically the RejuvenAir System, designed to treat Chronic Bronchitis in COPD patients by applying a precise thermal dose of liquid nitrogen.
Services
CSA Medical specializes in developing spray cryotherapy devices targeting chronic respiratory conditions. The company's core technology focuses on using liquid nitrogen spray to address the underlying causes of Chronic Bronchitis, a key factor in COPD (Chronic Obstructive Pulmonary Disease). CSA Medical is actively involved in clinical studies to validate the effectiveness of these treatments, aiming to reduce symptoms such as mucous production, cough, and inflammation in Chronic Bronchitis patients.
Products
The primary product developed by CSA Medical is the RejuvenAir System. This advanced cryosurgical device administers a precise thermal dose of -196°C liquid nitrogen to targeted areas within the lungs. The RejuvenAir System aims to treat the underlying causes of COPD with Chronic Bronchitis. It has received CE marking in the European Union and is currently limited to investigational use in the United States.
Clinical Trials
CSA Medical is conducting the SPRAY-CB Clinical Trial in the United States to evaluate the safety and effectiveness of the RejuvenAir System. The trial, which is currently recruiting patients, aims to explore metered cryospray treatments for Chronic Bronchitis. Previously, the first Randomized Controlled Study with RejuvenAir for Chronic Bronchitis showed clinically significant results in 2022, and in 2021, a Mechanism of Action Study was completed, focusing on COPD patients with Chronic Bronchitis.
Milestones
On February 7, 2024, CSA Medical announced the completion of its 500th Metered CryoSpray Procedure for treating Chronic Bronchitis. This milestone highlights the company's ongoing dedication to advancing cryotherapy technologies. Notably, the first Randomized Controlled Study with the RejuvenAir System demonstrated clinically significant results on September 6, 2022. Additionally, on May 13, 2021, CSA Medical completed enrollment for a Mechanism of Action Study for COPD patients with Chronic Bronchitis.